3E Bioventures Capital is a healthcare-focused venture capital firm investing in innovative therapeutic drugs, drug discovery platforms, and TechBio innovations. The firm manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and the United States.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (4 deals in the last 12 months). Their most common stage is series-a (46% of deals). Average disclosed round size is $49.7M (across 26 rounds with reported amounts).
Portfolio
27
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
MM
Maifeng Melford Yuan
Partner
CS
Christine Siying Wu
Investment Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
28 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Lysoway Therapeutics | Series A | $22M | Jun 2026 |
 OncoC4 | Series B | — | Oct 2025 |
 Rapafusyn | Series A | $44M | Sep 2025 |
 Arnatar | Series A | $52M | Aug 2025 |
 Acclaro | Series B | $23M | Jun 2025 |
| Rapafusyn | Series A | $44M | Jan 2025 |
 Arnatar Therapeutics | Series A | $52M | Dec 2024 |
 Smartlens | Series A | $6.1M | Jul 2023 |
| EEluminex Biosciences | Series B | — | Feb 2023 |
 Lipidio | Series A | $20M | Nov 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Dermaliq | Series A | $15M | Jan 2022 |
| DDewpoint | Series C | $150M | Jan 2022 |
 Alebund | Series B | $54.5M | Sep 2021 |
| CCardea | Unknown | $6.5M | Jan 2021 |
 Neural Galaxy | Series A | $77M | Jan 2021 |
| CCardea Bio | Series A | $7.5M | Jan 2021 |
 Shanton | Series A | $31.2M | Dec 2020 |
 Subtle Medical | Series A | $12.2M | Nov 2020 |
 OncoImmune | Series B | $56M | Sep 2020 |
| RRegenacy Pharmaceuticals | Series A | $30M | Jan 2020 |
 Profusa | Series C | $45M | Aug 2018 |
| RRefuge Biotechnologies | Series B | $25M | May 2018 |
 Ansun Biopharma | Series B | $80M | — |
| LLarkspur | Unknown | $35.5M | — |
Page 1 of 2
Top Co-Investors
Leaps by Bayer3 shared
Maverick Ventures3 shared
Mirae Asset3 shared
General Catalyst3 shared
Mubadala Ventures3 shared
ARCH Venture Partners3 shared
Samsara BioCapital3 shared
Polaris Partners3 shared
BioTrack Capital3 shared
Foothill Ventures2 shared
HMI Capital Management, L.P.2 shared
Atami Capital2 shared
The MBA Fund2 shared
ShangBay Capital2 shared
Danhua Capital2 shared
F-Prime Capital2 shared
Eight Roads2 shared
Gaorong Capital2 shared
Legend Star2 shared
Sand Hill Angels2 shared
Last updated: 9 September 2026